Prelude Therapeutics

Prelude Therapeutics to participate in the Citizens JMP Securities Hematology and Oncology Summit on Dec 2, 2024, featuring a fireside chat with CEO Kris Vaddi and CMO Jane Huang. The event will be webcast live and archived for 90 days on Prelude's website.

PRT3789, a first-in-class SMARCA2 degrader, shows encouraging anti-tumor activity and tolerability in SMARCA4-mutated NSCLC and esophageal cancer patients. No dose-limiting toxicities or serious adverse events reported. Dose escalation continues, with 7/26 patients showing tumor shrinkage. Conference call scheduled for September 13, 2024.

R.A.S., M.S.T., C.Y., R.N., H.S.R., M.D., A.J.C., E.S.-R., J.C.B., C.O., K.K., A.D.E., C.V., N.W., K.S.A., A.S.C., C.F., C.I., A.T., J.T., K.Y., L.H., K.G., F.M.H., T.S., A.L.A., P.B., P.N., G.L.H., W.F.S., J.P., P.P., A.D.M., D.Y., L.J.v.V., N.M.H., L.J.E. report various institutional research funding, advisory roles, consultancy, honoraria, patents, and stock ownership.